Prophylactic and therapeutic effects of twice-daily famciclovir administration on infectious upper respiratory disease in shelter-housed cats

Ann E. Cooper, Sara M Thomasy, Tracy L. Drazenovich, Philip H Kass, Sanskruti S. Potnis, Christian M. Leutenegger, David J Maggs

Research output: Contribution to journalArticle

Abstract

Objectives: In humans with herpetic disease, early or pre-emptive famciclovir therapy reduces disease duration and severity. This prospective, masked, placebo-controlled study tested therapeutic and prophylactic effects of two famciclovir doses given to cats for 7 days following shelter entry. Methods: Cats were assigned to prophylactic or therapeutic study arms based on clinical evidence of herpetic disease at study entry. Cats in the therapeutic arm received no treatment (n = 19), placebo (lactulose; n = 18) or famciclovir at ~30 (n = 21) or ~90 mg/kg (n = 20) orally q12h for 7 days. Cats in the prophylactic arm received no treatment (n = 25) or famciclovir at ~30 (n = 28) or ~90 mg/kg (n = 27) orally q12h for 7 days. Disease scores, body weight, conjunctival feline herpesvirus 1 (FHV-1) shedding, and adoption rates were recorded on days 1 (admission), 8 (end of therapy) and 15 (1 week after cessation of therapy). Results: No significant differences in clinical scores were observed among groups in the prophylactic or therapeutic arms at any of the three time points. However, within the therapeutic arm, viral shedding on day 8 was significantly higher in cats receiving no treatment than in those receiving ~30 or ~90 mg/kg famciclovir, and this effect persisted 1 week after famciclovir was stopped (day 15) only in cats receiving ~30 mg/kg, although this approached significance in cats receiving ~90 mg/kg. No significant differences in adoption rates were detected among groups in either arm throughout the study. Conclusions and relevance: Although we did not demonstrate a statistically or clinically significant effect of famciclovir administration upon clinical signs of infectious upper respiratory disease or adoption, when it was administered at ~30 or ~90 mg/kg q12h for 1 week famciclovir reduced conjunctival FHV-1 shedding. This suggests a potential role in interrupting the infectious cycle within a shelter population; however cost in time and resources, and stress and pathogen transmission induced by oral administration should be considered.

Original languageEnglish (US)
JournalJournal of Feline Medicine and Surgery
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Therapeutic Uses
respiratory tract diseases
Cats
cats
therapeutics
Felid herpesvirus 1
Therapeutics
Herpesviridae
placebos
Felidae
lactulose
viral shedding
Placebos
famciclovir
Virus Shedding
Lactulose
Infectious Disease Transmission
oral administration
Oral Administration
duration

Keywords

  • Antiviral therapy
  • feline herpesvirus
  • ocular disease
  • penciclovir
  • population health
  • viral prophylaxis

ASJC Scopus subject areas

  • Small Animals

Cite this

Prophylactic and therapeutic effects of twice-daily famciclovir administration on infectious upper respiratory disease in shelter-housed cats. / Cooper, Ann E.; Thomasy, Sara M; Drazenovich, Tracy L.; Kass, Philip H; Potnis, Sanskruti S.; Leutenegger, Christian M.; Maggs, David J.

In: Journal of Feline Medicine and Surgery, 01.01.2018.

Research output: Contribution to journalArticle

@article{df6db6743bb6464bbee69e6983504c99,
title = "Prophylactic and therapeutic effects of twice-daily famciclovir administration on infectious upper respiratory disease in shelter-housed cats",
abstract = "Objectives: In humans with herpetic disease, early or pre-emptive famciclovir therapy reduces disease duration and severity. This prospective, masked, placebo-controlled study tested therapeutic and prophylactic effects of two famciclovir doses given to cats for 7 days following shelter entry. Methods: Cats were assigned to prophylactic or therapeutic study arms based on clinical evidence of herpetic disease at study entry. Cats in the therapeutic arm received no treatment (n = 19), placebo (lactulose; n = 18) or famciclovir at ~30 (n = 21) or ~90 mg/kg (n = 20) orally q12h for 7 days. Cats in the prophylactic arm received no treatment (n = 25) or famciclovir at ~30 (n = 28) or ~90 mg/kg (n = 27) orally q12h for 7 days. Disease scores, body weight, conjunctival feline herpesvirus 1 (FHV-1) shedding, and adoption rates were recorded on days 1 (admission), 8 (end of therapy) and 15 (1 week after cessation of therapy). Results: No significant differences in clinical scores were observed among groups in the prophylactic or therapeutic arms at any of the three time points. However, within the therapeutic arm, viral shedding on day 8 was significantly higher in cats receiving no treatment than in those receiving ~30 or ~90 mg/kg famciclovir, and this effect persisted 1 week after famciclovir was stopped (day 15) only in cats receiving ~30 mg/kg, although this approached significance in cats receiving ~90 mg/kg. No significant differences in adoption rates were detected among groups in either arm throughout the study. Conclusions and relevance: Although we did not demonstrate a statistically or clinically significant effect of famciclovir administration upon clinical signs of infectious upper respiratory disease or adoption, when it was administered at ~30 or ~90 mg/kg q12h for 1 week famciclovir reduced conjunctival FHV-1 shedding. This suggests a potential role in interrupting the infectious cycle within a shelter population; however cost in time and resources, and stress and pathogen transmission induced by oral administration should be considered.",
keywords = "Antiviral therapy, feline herpesvirus, ocular disease, penciclovir, population health, viral prophylaxis",
author = "Cooper, {Ann E.} and Thomasy, {Sara M} and Drazenovich, {Tracy L.} and Kass, {Philip H} and Potnis, {Sanskruti S.} and Leutenegger, {Christian M.} and Maggs, {David J}",
year = "2018",
month = "1",
day = "1",
doi = "10.1177/1098612X18789719",
language = "English (US)",
journal = "Journal of Feline Medicine and Surgery",
issn = "1098-612X",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Prophylactic and therapeutic effects of twice-daily famciclovir administration on infectious upper respiratory disease in shelter-housed cats

AU - Cooper, Ann E.

AU - Thomasy, Sara M

AU - Drazenovich, Tracy L.

AU - Kass, Philip H

AU - Potnis, Sanskruti S.

AU - Leutenegger, Christian M.

AU - Maggs, David J

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Objectives: In humans with herpetic disease, early or pre-emptive famciclovir therapy reduces disease duration and severity. This prospective, masked, placebo-controlled study tested therapeutic and prophylactic effects of two famciclovir doses given to cats for 7 days following shelter entry. Methods: Cats were assigned to prophylactic or therapeutic study arms based on clinical evidence of herpetic disease at study entry. Cats in the therapeutic arm received no treatment (n = 19), placebo (lactulose; n = 18) or famciclovir at ~30 (n = 21) or ~90 mg/kg (n = 20) orally q12h for 7 days. Cats in the prophylactic arm received no treatment (n = 25) or famciclovir at ~30 (n = 28) or ~90 mg/kg (n = 27) orally q12h for 7 days. Disease scores, body weight, conjunctival feline herpesvirus 1 (FHV-1) shedding, and adoption rates were recorded on days 1 (admission), 8 (end of therapy) and 15 (1 week after cessation of therapy). Results: No significant differences in clinical scores were observed among groups in the prophylactic or therapeutic arms at any of the three time points. However, within the therapeutic arm, viral shedding on day 8 was significantly higher in cats receiving no treatment than in those receiving ~30 or ~90 mg/kg famciclovir, and this effect persisted 1 week after famciclovir was stopped (day 15) only in cats receiving ~30 mg/kg, although this approached significance in cats receiving ~90 mg/kg. No significant differences in adoption rates were detected among groups in either arm throughout the study. Conclusions and relevance: Although we did not demonstrate a statistically or clinically significant effect of famciclovir administration upon clinical signs of infectious upper respiratory disease or adoption, when it was administered at ~30 or ~90 mg/kg q12h for 1 week famciclovir reduced conjunctival FHV-1 shedding. This suggests a potential role in interrupting the infectious cycle within a shelter population; however cost in time and resources, and stress and pathogen transmission induced by oral administration should be considered.

AB - Objectives: In humans with herpetic disease, early or pre-emptive famciclovir therapy reduces disease duration and severity. This prospective, masked, placebo-controlled study tested therapeutic and prophylactic effects of two famciclovir doses given to cats for 7 days following shelter entry. Methods: Cats were assigned to prophylactic or therapeutic study arms based on clinical evidence of herpetic disease at study entry. Cats in the therapeutic arm received no treatment (n = 19), placebo (lactulose; n = 18) or famciclovir at ~30 (n = 21) or ~90 mg/kg (n = 20) orally q12h for 7 days. Cats in the prophylactic arm received no treatment (n = 25) or famciclovir at ~30 (n = 28) or ~90 mg/kg (n = 27) orally q12h for 7 days. Disease scores, body weight, conjunctival feline herpesvirus 1 (FHV-1) shedding, and adoption rates were recorded on days 1 (admission), 8 (end of therapy) and 15 (1 week after cessation of therapy). Results: No significant differences in clinical scores were observed among groups in the prophylactic or therapeutic arms at any of the three time points. However, within the therapeutic arm, viral shedding on day 8 was significantly higher in cats receiving no treatment than in those receiving ~30 or ~90 mg/kg famciclovir, and this effect persisted 1 week after famciclovir was stopped (day 15) only in cats receiving ~30 mg/kg, although this approached significance in cats receiving ~90 mg/kg. No significant differences in adoption rates were detected among groups in either arm throughout the study. Conclusions and relevance: Although we did not demonstrate a statistically or clinically significant effect of famciclovir administration upon clinical signs of infectious upper respiratory disease or adoption, when it was administered at ~30 or ~90 mg/kg q12h for 1 week famciclovir reduced conjunctival FHV-1 shedding. This suggests a potential role in interrupting the infectious cycle within a shelter population; however cost in time and resources, and stress and pathogen transmission induced by oral administration should be considered.

KW - Antiviral therapy

KW - feline herpesvirus

KW - ocular disease

KW - penciclovir

KW - population health

KW - viral prophylaxis

UR - http://www.scopus.com/inward/record.url?scp=85052589661&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052589661&partnerID=8YFLogxK

U2 - 10.1177/1098612X18789719

DO - 10.1177/1098612X18789719

M3 - Article

C2 - 30099962

AN - SCOPUS:85052589661

JO - Journal of Feline Medicine and Surgery

JF - Journal of Feline Medicine and Surgery

SN - 1098-612X

ER -